BRPI0412159A - emprego - Google Patents

emprego

Info

Publication number
BRPI0412159A
BRPI0412159A BRPI0412159-7A BRPI0412159A BRPI0412159A BR PI0412159 A BRPI0412159 A BR PI0412159A BR PI0412159 A BRPI0412159 A BR PI0412159A BR PI0412159 A BRPI0412159 A BR PI0412159A
Authority
BR
Brazil
Prior art keywords
job
roscovitine
medicament
preparation
pharmaceutically acceptable
Prior art date
Application number
BRPI0412159-7A
Other languages
English (en)
Inventor
Athos Giannella-Borradori
Paul Moss
Tatjana Stankovic
Simon Green
David Lane
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Publication of BRPI0412159A publication Critical patent/BRPI0412159A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"EMPREGO". A presente invenção refere-se ao emprego da roscovitina, ou um sal farmaceuticamente aceitável da mesma, na preparação de um medicamento para tratamento de leucemia linfocítica crónica.
BRPI0412159-7A 2003-06-30 2004-06-30 emprego BRPI0412159A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0315259.2A GB0315259D0 (en) 2003-06-30 2003-06-30 Use
PCT/GB2004/002812 WO2005002584A1 (en) 2003-06-30 2004-06-30 Use of roscovitine for treating lymphocytic leukemia

Publications (1)

Publication Number Publication Date
BRPI0412159A true BRPI0412159A (pt) 2006-08-22

Family

ID=27676349

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412159-7A BRPI0412159A (pt) 2003-06-30 2004-06-30 emprego

Country Status (10)

Country Link
US (1) US20050153991A1 (pt)
EP (1) EP1638572A1 (pt)
JP (1) JP2007526882A (pt)
CN (1) CN1816338A (pt)
AU (1) AU2004253337A1 (pt)
BR (1) BRPI0412159A (pt)
CA (1) CA2530116A1 (pt)
GB (1) GB0315259D0 (pt)
IL (1) IL172718A0 (pt)
WO (1) WO2005002584A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
WO2006132675A2 (en) * 2004-12-20 2006-12-14 University Of South Florida Xiap-targeted prostate cancer therapy
FR2920776B1 (fr) 2007-09-12 2012-09-28 Centre Nat Rech Scient Utilisation de derives de purine pour la fabrication d'un medicament
WO2010103473A1 (en) * 2009-03-10 2010-09-16 Chu De Brest Method of treatment of polycystic diseases and chronic lymphocytic leukemia
JP6286421B2 (ja) 2012-05-15 2018-02-28 サイクラセル リミテッド サパシタビン及びセリシクリブの投与レジメン
US9505764B2 (en) * 2013-04-17 2016-11-29 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
HK1251655A1 (zh) 2015-04-20 2019-02-01 Tolero Pharmaceuticals, Inc. 通过线粒体分析预测对阿伏西地的应答
KR102608921B1 (ko) 2015-05-18 2023-12-01 스미토모 파마 온콜로지, 인크. 생체 이용률이 증가된 알보시딥 프로드러그
JP7083497B2 (ja) 2015-08-03 2022-06-13 スミトモ ファーマ オンコロジー， インコーポレイテッド がんの処置のための併用療法
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
AU2017379847B2 (en) 2016-12-19 2022-05-26 Sumitomo Pharma Oncology, Inc. Profiling peptides and methods for sensitivity profiling
TWI787284B (zh) 2017-06-22 2022-12-21 美商西建公司 以b型肝炎病毒感染表徵之肝細胞癌之治療
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
CN116251188A (zh) * 2023-01-09 2023-06-13 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） Stat1抑制剂在制备b细胞淋巴癌放射增敏药物中的应用及该药物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
AU753015B2 (en) * 1998-03-04 2002-10-03 Cyclacel Limited Cyclin dependent kinase inhibitor
US20050004007A1 (en) * 2000-09-12 2005-01-06 Steven Grant Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents
US20030229105A1 (en) * 2002-05-21 2003-12-11 Cyclacel Limited Treatment of autoimmune disorders
AU2003258061A1 (en) * 2002-08-02 2004-02-23 Salmedix, Inc. Therapeutic inhibitionof protein kinases in cancer cells

Also Published As

Publication number Publication date
CA2530116A1 (en) 2005-01-13
WO2005002584A1 (en) 2005-01-13
JP2007526882A (ja) 2007-09-20
IL172718A0 (en) 2006-04-10
CN1816338A (zh) 2006-08-09
AU2004253337A1 (en) 2005-01-13
US20050153991A1 (en) 2005-07-14
EP1638572A1 (en) 2006-03-29
GB0315259D0 (en) 2003-08-06

Similar Documents

Publication Publication Date Title
BRPI0412159A (pt) emprego
BRPI0416628A (pt) uso de compostos orgánicos
WO2003009838A1 (en) Use of stilbene compounds in preparing medicaments for treating or preventing diabetes and diseases associated with retrovirus
TW200635923A (en) Tricyclic heterocycles, their manufacture and use as pharmaceutical agents
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
BRPI0408198A (pt) processo para tratar e prevenir hiperparatireoidismo com compostos de vitamina d2 ou d4
DE60134324D1 (de) NEUE HEILMITTEL FüR KREBS
BR0113590A (pt) 7-oxo-piridopirimidinas
BRPI0407097A (pt) Antagonista do casr
BRPI0407234A (pt) Heterociclos substituìdos
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
GEP20094826B (en) 3- or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
BR0110210A (pt) Compostos para o tratamento de fibromialgia e sìndrome de fadiga crÈnica
ATE499939T1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
BR0215016A (pt) Piridoquinoxalinas antivirìcas
BRPI0408295A (pt) uso de um composto
BR0011578A (pt) Utilização do s-enantiÈmero de citalopram para tratamento de distúrbio de ansiedade geral ou ataques de pânico
TW200531688A (en) Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
BRPI0407679A (pt) sulfamatos de estra-1,3,5(10)-trien-3-ila 2-substituìdos ativos antitumor
ZA200707486B (en) Use of 2-(2-nitro-4-trifluoromenthylbenzoyl)-1,3- cyclohexanedione in the treatment of parkinson's disease
TW200719899A (en) Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents
BRPI0513943A (pt) uso de um composto ou de um sal farmaceuticamente aceitável
SE0102058D0 (sv) New Salts II
BRPI0414527A (pt) tratamento de tumores estromáticos gastrointestinais com imatinib e midostaurina

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]